Compile Data Set for Download or QSAR
Report error Found 55 Enz. Inhib. hit(s) with all data for entry = 10759
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565119(US11414402, Example 30 | 3-((4-(4-chlorophenyl)pip...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565120(US11414402, Example 31 | (S)-3-((4-(4-chlorophenyl...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565121(US11414402, Example 32 | (R)-3-((4-(4-chlorophenyl...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565101(US11414402, Example 14 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565102(US11414402, Example 15 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565098(US11414402, Example 11 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565100(US11414402, Example 13 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565105(US11414402, Example 19 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565103(US11414402, Example 16 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565115(US11414402, Example 23 | rac-(4aR,7aS)-4-(4-methyl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565106(US11414402, Example 20 | (R) N-(1-cyanopyrrolidin-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565113(US11414402, Example 21 | (3aR,6aR)-1-((4-(pyridin-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565109(US11414402, Example 26 | N-([1,1'-biphenyl]-4-yl)-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565107(US11414402, Example 24 | N-(5-(N-(1-cyanopyrrolidi...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565108(US11414402, Example 25 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565105(US11414402, Example 19 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565117(US11414402, Example 28 | (3-((4-(pyridin-2-yl)pipe...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565123(US11414402, Example 34 | 3-((3-(4-chlorophenyl)aze...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565090(US11414402, Example 1 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565124(US11414402, Example 35 | (S)-3-((3-(4-chlorophenyl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565122(US11414402, Example 33 | 3-((4-benzylpiperidin-1- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565093(US11414402, Example 4 | (S)-N-(1-cyanopyrrolidin- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565091(US11414402, Example 2 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565125(US11414402, Example 36 | (R)-3-((3-(4-chlorophenyl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565092(US11414402, Example 3 | (R)-N-(1-cyanopyrrolidin- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565097(US11414402, Example 9 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565096(US11414402, Example 8 | (4-(benzyloxy)-N-(1- cyano...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565104(US11414402, Example 18 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565093(US11414402, Example 4 | (S)-N-(1-cyanopyrrolidin- ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565091(US11414402, Example 2 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565112(US11414402, Example 17 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565097(US11414402, Example 9 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565096(US11414402, Example 8 | (4-(benzyloxy)-N-(1- cyano...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565102(US11414402, Example 15 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565099(US11414402, Example 12 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565100(US11414402, Example 13 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565106(US11414402, Example 20 | (R) N-(1-cyanopyrrolidin-...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565118(US11414402, Example 29 | 3-((4-(pyrimidin-2-yl)pip...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565108(US11414402, Example 25 | N-(1-cyanopyrrolidin-3-yl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM50418001(CHEMBL1672421 | US11414402, Example 6)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565111(US11414402, Example 10 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM50417989(CHEMBL1672422 | US11414402, Example 7)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565090(US11414402, Example 1 | N-(1-cyanopyrrolidin-3- yl...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM50095489(N-(1-Cyano-pyrrolidin-3-yl)-benzenesulfonamide | N...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565092(US11414402, Example 3 | (R)-N-(1-cyanopyrrolidin- ...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565114(US11414402, Example 22 | rac-(4aR,7aR)-4-tosylhexa...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565098(US11414402, Example 11 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM50418001(CHEMBL1672421 | US11414402, Example 6)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565101(US11414402, Example 14 | N-(1-cyanopyrrolidin-3- y...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM565116(US11414402, Example 27 | 3-((4-(4-fluorophenyl)pip...)
Affinity DataIC50: 5.50E+4nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2022
Entry Details
US Patent

Displayed 1 to 50 (of 55 total ) | Next | Last >>
Jump to: